{"product_id":"amgen-ansoff-matrix","title":"Amgen Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Amgen Amsoff Matrix Analysis gives a clear view of Amgen’s growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the analysis, so you can review the actual content and style before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepatha and Prolia defend the mature base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Repatha and Prolia still anchor Amgen's mature base in chronic-care markets where diagnosis keeps rising and switching costs stay high. With FY2025 revenue near $33 billion, even a 1% share gain is about $330 million in sales, so payer access, specialist adoption, and outcomes data matter more than pure volume.\u003c\/p\u003e\n\u003cp\u003eThis is a defense-first penetration play: protect formulary access, keep prescribers loyal, and turn rising diagnosis rates into repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire deepens share in 2 respiratory indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTezspire is a focused market penetration play in 2 approved respiratory uses: severe asthma and chronic rhinosinusitis with nasal polyps. In 2025, Amgen and AstraZeneca kept pushing specialist education, payer access, and real-world evidence to lift use inside those same labels, not expand the molecule itself.\u003c\/p\u003e\n\u003cp\u003eThe play is about deeper share, not new indication risk, so every extra prescription comes from better diagnosis, referral, and reimbursement. The AstraZeneca partnership also widens respiratory reach while Tezspire stays centered on the same biologic target.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars harvest share in 5 branded copies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen uses a five-product biosimilar stack, Amjevita, Mvasi, Kanjinti, Ogivri, and Riabni, to win formulary access and price share in the same developed markets. That is classic market penetration: replace higher-cost reference biologics instead of opening new markets. The mix also helps offset pressure on Enbrel, which remains a key legacy brand in a tougher pricing cycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnbrel defends a 25-year inflammatory franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnbrel still defends a 25-year inflammatory franchise by holding onto current patients through persistence, support, and payer access, even as biosimilars pressure price and share. In Amgen’s 2025 mix, that steady cash flow still matters because a mature brand like Enbrel helps fund one of Amgen’s costliest engines: R\u0026amp;D. That makes this a defensive move in the Ansoff Matrix, but a useful one, because keeping a large base alive can still finance future growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty channels lift uptake for new launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen is pushing new launches like Imdelltra through oncology clinics, infusion sites, and specialty pharmacy networks, which helps reach the right patients faster than broad consumer marketing. In 2025, that channel mix mattered because specialty drugs win on clinical proof and quick reimbursement, not mass awareness. With sales in more than 100 countries, execution across these channels is a key market-penetration lever for Amgen.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s FY2025 growth hinges on deeper share gains across core brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Amgen’s market penetration relied on deeper use of Repatha, Prolia, Tezspire, and legacy brands like Enbrel in the same core markets. With revenue near $33 billion, even a 1% share gain is about $330 million. Biosimilars like Amjevita and Mvasi also push price share in developed markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 lever\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore brands\u003c\/td\u003e\n\u003ctd\u003eRepatha, Prolia, Tezspire\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e~$33B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1% share gain\u003c\/td\u003e\n\u003ctd\u003e~$330M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Amgen’s growth strategy through the four core directions of the Amsoff Matrix\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOffers a quick, visual Amgen Ansoff Matrix that simplifies growth strategy decisions and reduces planning friction.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMore than 100 countries extend existing brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen already sells in more than 100 countries, so market development is mainly about taking approved drugs into new reimbursement systems and care settings. In 2025, that means more launches in geographies where local access rules and pricing differ, not new products. This fits specialty medicines best, because high unmet need makes payer and physician adoption faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHorizon added 3 rare-disease brands in 2023\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHorizon Therapeutics added three rare-disease brands to Amgen in 2023: Tepezza, Krystexxa, and Uplizna. That move pushed Amgen into ophthalmology, gout, and neuroimmunology, giving its sales force and medical-affairs teams three new commercial markets to work. At about $28 billion, the deal shows Amgen’s push beyond oncology and inflammation into higher-growth specialty care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars move into public and hospital tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen can move mature biosimilars into national tenders, hospital formularies, and public reimbursement channels that reward lower acquisition cost. This fits Europe and Japan, where branded biologic pricing stays under pressure and tender wins can quickly add volume without new discovery risk. It turns one approved molecule into new geographic revenue streams, with biosimilars now a key growth line across major off-patent biologic classes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire benefits from AstraZeneca’s global reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen and AstraZeneca co-develop Tezspire, so Amgen can use AstraZeneca’s respiratory sales force to reach specialists in more ex-U.S. markets without building a full local network. Tezspire now has 2 approved indications, severe asthma and chronic rhinosinusitis with nasal polyps, which broadens the same drug across more channels. That makes this a clean market development play: same asset, wider geography, lower country-entry cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity oncology widens the launch footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen often launches specialty drugs in top U.S. cancer centers first, then pushes into community oncology and foreign affiliates. That matters for Imdelltra and Tavneos because uptake depends on physician education, infusion readiness, and referral flow, not just label approval. It turns one early market into several and can lift volume without a full new launch.\u003c\/p\u003e\n\u003cp\u003eThis is a low-cost growth step after initial proof in academic sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s 2025 Growth Play: Expanding Approved Drugs Globally\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Amgen’s market development is about pushing approved drugs into new countries, payers, and care settings, not new launches. With sales in 100+ countries and the $28.3 billion Horizon deal, Amgen can widen Tepezza, Krystexxa, Uplizna, and Tezspire across specialty channels and reimbursement systems.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeography\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon deal\u003c\/td\u003e\n\u003ctd\u003e$28.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTezspire\u003c\/td\u003e\n\u003ctd\u003e2 approved indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoute\u003c\/td\u003e\n\u003ctd\u003eTenders, formularies, payer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eAmgen Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the actual Amgen Amsoff Matrix Analysis document you’ll receive after purchase. The preview below is taken directly from the full report, so there are no surprises—just the same professional content in complete form. Once you buy, the entire document is unlocked and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMariTide targets obesity and diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's MariTide is the core new-product bet in obesity and type 2 diabetes, and its mid-2020s Phase 2 data showed up to 20.9% mean weight loss at 52 weeks in obesity. In type 2 diabetes, the same program also posted large A1c cuts, which supports a broader metabolic label.\u003c\/p\u003e\n\u003cp\u003eIf Phase 3 confirms those results, MariTide could enter a market where obesity drugs are already tracking toward $100 billion-plus in annual sales this decade.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlpasiran advances as an Lp(a) therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlpasiran targets lipoprotein(a), or Lp(a), a heritable cardiovascular risk factor that statins do not lower well; in phase 2 OCEAN(a)-DOSE, it cut Lp(a) by more than 95% at 36 weeks. Amgen is pushing it because Lp(a) biology could open a new prevention market, not just another crowded LDL space. The upside hinges on outcomes data from OCEAN(a)-Outcomes and on wider Lp(a) testing, which still is not routine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImdelltra extends T-cell redirection beyond SCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImdelltra, approved in 2024 for extensive-stage small cell lung cancer after platinum therapy, is now being pushed into earlier lines and combination regimens. That is pure product development: one approved asset, more eligible patients, and a longer treatment window. Small cell lung cancer is only about 13% to 15% of lung cancers, so any label expansion could lift Amgen from a narrow salvage niche into a much larger oncology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXaluritamig broadens the oncology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXaluritamig extends Amgen’s oncology pipeline beyond legacy biologics, adding a next-gen engineered immunotherapy bet on growth outside Enbrel and Prolia. It targets metastatic castration-resistant prostate cancer, a large field with about 313,000 new prostate cancer cases and 35,000 deaths in the U.S. in 2025. If it works, it could help diversify Amgen’s mix toward higher-upside oncology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle upgrades protect older biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen uses line extensions, device upgrades, and formulation work to keep older biologics clinically relevant, so products can stay in use longer even as patent cliffs hit. That is a smart product development move in the Ansoff Matrix: it deepens value from existing products without needing a full reset. Small gains in ease of use can matter a lot across 12-month refill cycles.\u003c\/p\u003e\n\u003cp\u003eThe same R\u0026amp;D base supports this across oncology, inflammation, and cardiovascular disease, helping Amgen defend share while extending franchise life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Pipeline: MariTide, Olpasiran and Imdelltra Drive New Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's product development is led by MariTide, with phase 2 obesity data showing up to 20.9% mean weight loss at 52 weeks and strong A1c cuts in type 2 diabetes. Olpasiran cut Lp(a) by more than 95% in phase 2, so it could open a new prevention market. Imdelltra is being moved earlier in small cell lung cancer, and xaluritamig adds a new oncology shot on goal.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 readout\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMariTide\u003c\/td\u003e\n\u003ctd\u003e20.9% weight loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlpasiran\u003c\/td\u003e\n\u003ctd\u003e95%+ Lp(a) cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImdelltra\u003c\/td\u003e\n\u003ctd\u003eEarlier-line push\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHorizon added 3 rare-disease businesses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen’s Horizon deal was a clear diversification move: it added Tepezza, Krystexxa, and Uplizna, three rare-disease brands bought for about $27.8 billion in 2023. In 2025, those assets widened Amgen’s reach beyond its core chronic-care base. \u003c\/p\u003e\n\u003cp\u003eTepezza, Krystexxa, and Uplizna serve very different patient groups and specialists. That lowers reliance on a narrower set of oncology and inflammation assets. \u003c\/p\u003e\n\u003cp\u003eSo this fits diversification in the Ansoff Matrix: new products, new patients, and less portfolio concentration risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemoCentryx brought Tavneos into vasculitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen’s 2022 ChemoCentryx deal, valued at about $3.7 billion, added Tavneos, a therapy for ANCA-associated vasculitis. By fiscal 2025, that gave Amgen exposure to a niche autoimmune market with a different physician set, payer rules, and patient flow than its legacy biologics. This is diversification because the product, patients, and sales path all sit outside Amgen’s main blockbuster playbook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMariTide pushes Amgen into obesity medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eObesity is a new market for Amgen, and MariTide is its clearest entry. In 2024, Wegovy and Zepbound sales topped $16 billion, so the field is already huge and crowded.\u003c\/p\u003e\n\u003cp\u003ePhase 2 data showed MariTide produced up to 20% mean weight loss at 52 weeks, but tolerability and payer coverage will decide uptake. That matters because monthly dosing could help, yet nausea and reimbursement can still slow use.\u003c\/p\u003e\n\u003cp\u003eFor Amgen, success would add a fresh growth engine beyond oncology, nephrology, and inflammation. It is a diversification move with real upside, but also real execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLp(a) biology opens a new prevention category\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen’s Lp(a) program can diversify it into prevention, not just another LDL-lowering lane. Lipoprotein(a) is elevated in about 20% of people and, in 2025, still has no widely approved targeted therapy, so the unmet need is real.\u003c\/p\u003e\n\u003cp\u003eIf outcomes data are strong, Amgen could help define a new cardiovascular market rather than fight only in the old statin and PCSK9 space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology bispecifics add modality diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eImdelltra and xaluritamig give Amgen modality diversification by moving beyond standard antibodies into T-cell engagers and other engineered formats. That widens Amgen’s oncology mix at the therapeutic level too, with Imdelltra already in relapsed small-cell lung cancer and xaluritamig aimed at advanced prostate cancer. The trade-off is higher science and launch risk, but if these programs scale, they can anchor Amgen’s growth platform for the next 5 to 10 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s 2025 Diversification Push: New Bets, New Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen’s diversification in the Amsoff Matrix is clear in 2025: Horizon’s rare-disease brands, ChemoCentryx’s Tavneos, and MariTide all push Amgen into new patient groups and new markets. That cuts dependence on its core oncology and inflammation base while adding higher-risk, higher-upside growth lanes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon\u003c\/td\u003e\n\u003ctd\u003eAbout $27.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemoCentryx\u003c\/td\u003e\n\u003ctd\u003eAbout $3.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMariTide\u003c\/td\u003e\n\u003ctd\u003eUp to 20% weight loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53647240560982,"sku":"amgen-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/amgen-ansoff-analysis.webp?v=1778875290","url":"https:\/\/balancedscorecardexamples.com\/products\/amgen-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}